A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Rui Shi, Chao Shan, Xiaomin Duan, Zhihai Chen, Peipei Liu, Jinwen Song, Tao Song, Xiaoshan Bi, Chao Han, Lianao Wu, Ge Gao, Xue Hu, Yanan Zhang, Zhou Tong, Weijin Huang, William Jun Liu, Guizhen Wu, Bo Zhang, Lan Wang, Jianxun Qi, Hui Feng, Fu-Sheng Wang (), Qihui Wang (), George Fu Gao (), Zhiming Yuan () and Jinghua Yan ()
Additional contact information
Rui Shi: Chinese Academy of Sciences
Chao Shan: Chinese Academy of Sciences
Xiaomin Duan: Chinese Academy of Sciences
Zhihai Chen: Capital Medical University
Peipei Liu: Chinese Center for Disease Control and Prevention
Jinwen Song: National Clinical Research Center for Infectious Diseases
Tao Song: Chinese Academy of Sciences
Xiaoshan Bi: Chinese Academy of Sciences
Chao Han: Chinese Academy of Sciences
Lianao Wu: Anhui University
Ge Gao: Chinese Academy of Sciences
Xue Hu: Chinese Academy of Sciences
Yanan Zhang: Chinese Academy of Sciences
Zhou Tong: Chinese Academy of Sciences
Weijin Huang: National Institutes for Food and Drug Control
William Jun Liu: Chinese Center for Disease Control and Prevention
Guizhen Wu: Chinese Center for Disease Control and Prevention
Bo Zhang: Chinese Academy of Sciences
Lan Wang: National Institutes for Food and Drug Control
Jianxun Qi: Chinese Academy of Sciences
Hui Feng: Shanghai Junshi Biosciences Co. Ltd
Fu-Sheng Wang: National Clinical Research Center for Infectious Diseases
Qihui Wang: Chinese Academy of Sciences
George Fu Gao: Chinese Academy of Sciences
Zhiming Yuan: Chinese Academy of Sciences
Jinghua Yan: Chinese Academy of Sciences

Nature, 2020, vol. 584, issue 7819, 120-124

Abstract: Abstract An outbreak of coronavirus disease 2019 (COVID-19)1–3, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)4, has spread globally. Countermeasures are needed to treat and prevent further dissemination of the virus. Here we report the isolation of two specific human monoclonal antibodies (termed CA1 and CB6) from a patient convalescing from COVID-19. CA1 and CB6 demonstrated potent SARS-CoV-2-specific neutralization activity in vitro. In addition, CB6 inhibited infection with SARS-CoV-2 in rhesus monkeys in both prophylactic and treatment settings. We also performed structural studies, which revealed that CB6 recognizes an epitope that overlaps with angiotensin-converting enzyme 2 (ACE2)-binding sites in the SARS-CoV-2 receptor-binding domain, and thereby interferes with virus–receptor interactions by both steric hindrance and direct competition for interface residues. Our results suggest that CB6 deserves further study as a candidate for translation to the clinic.

Date: 2020
References: Add references at CitEc
Citations: View citations in EconPapers (14)

Downloads: (external link)
https://www.nature.com/articles/s41586-020-2381-y Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:584:y:2020:i:7819:d:10.1038_s41586-020-2381-y

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/s41586-020-2381-y

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().